Among the whole plethora of PDE4 inhibitors, Roflumilast was initially approved for the treatment of COPD and asthma, apremilast for the treatment of psoriasis and psoriatic arthritis and crisaborole was approved for the treatment of AD. This evidence concerns the gene PDE4A and psoriasis.